877064-78-3Relevant academic research and scientific papers
4-[18F]Fluoro-m-hydroxyphenethylguanidine: A radiopharmaceutical for quantifying regional cardiac sympathetic nerve density with positron emission tomography
Jang, Keun Sam,Jung, Yong-Woon,Gu, Guie,Koeppe, Robert A.,Sherman, Phillip S.,Quesada, Carole A.,Raffel, David M.
, p. 7312 - 7323 (2013)
4-[18F]Fluoro-m-hydroxyphenethylguanidine ([18F]4F- MHPG, [18F]1) is a new cardiac sympathetic nerve radiotracer with kinetic properties favorable for quantifying regional nerve density with PET and tracer kinetic analysis. An automated synthesis of [18F]1 was developed in which the intermediate 4-[18F]fluoro-m-tyramine ([ 18F]16) was prepared using a diaryliodonium salt precursor for nucleophilic aromatic [18F]fluorination. In PET imaging studies in rhesus macaque monkeys, [18F]1 demonstrated high quality cardiac images with low uptake in lungs and the liver. Compartmental modeling of [ 18F]1 kinetics provided net uptake rate constants Ki (mL/min/g wet), and Patlak graphical analysis of [18F]1 kinetics provided Patlak slopes Kp (mL/min/g). In pharmacological blocking studies with the norepinephrine transporter inhibitor desipramine (DMI), each of these quantitative measures declined in a dose-dependent manner with increasing DMI doses. These initial results strongly suggest that [18F]1 can provide quantitative measures of regional cardiac sympathetic nerve density in human hearts using PET.
Scalable synthesis of cryptophane-1.1.1 and its functionalization
Traore, Tenin,Delacour, Lea,Berthault, Patrick,Cintrat, Jean-Christophe,Rousseau, Bernard
, p. 960 - 962 (2010)
(Figure Presented) Cryptophanes, cage molecules for which xenon exhibits a high affinity, are good candidates for xenon biosenslng. Cryptophane-1.1.1 (1) exhibits the highest binding constant for xenon encapsulation In organic solution determined to date. This property suggests that the cryptophane-1.1.1 core (1) Is optimal for sensing applications. A high-yielding scalable synthesis of compound 1 is reported as well as an easy way to functionalize it.
1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS
-
Page/Page column 57, (2015/02/25)
The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; 5 (IA) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
NOVEL 3-PHENYLPROPANOIC COMPOUND ACTIVATORS OF RECEPTORS OF PPAR TYPE AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF
-
, (2010/07/04)
Novel 3-phenylpropanoic acid compounds have the general formula (I) below: and are formulated into pharmaceutical compositions for administration in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune dis
NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
-
Page/Page column 36; 51, (2010/10/20)
The invention relates to novel biaromatic compounds that correspond to the general formula (I) and also to the method for preparing them, and to their use in pharmaceutical compositions for use in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or lipid metabolism-related diseases), or alternatively in cosmetic compositions.
